Home Tools
Log in
Cart

PDGFR

Platelet-derived growth factor receptors (PDGF-R) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGF-R, alpha and beta each encoded by a different gene. Depending on which growth factor is bound, PDGF-R homo- or heterodimerizes.
Cat. No. Product name CAS No. Purity Chemical Structure
T8541 Lenvatinib mesylate 857890-39-2 99.79%
Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
T0520 Lenvatinib 417716-92-8 99.8000%
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
T0093 Sorafenib tosylate 475207-59-1 99.81%
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
T7861 Flumatinib mesylate 895519-91-2 99.82%
Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
T1895 SKLB 610 1125780-41-7 99.83%
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
T6920 ON123300 1357470-29-1 99.84%
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T0097L Pazopanib 444731-52-6 99.84%
Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1,...
T1792 Regorafenib 755037-03-7 99.87%
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T60110 KN1022 205255-11-4 99.88%
KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
T0093L Sorafenib 284461-73-0 99.89%
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
T2446 KI8751 228559-41-9 99.9%
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T2609 Masitinib 790299-79-5 99.91%
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
T1777 Nintedanib 656247-17-5 99.92%
Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).
T8544 Masitinib mesylate 1048007-93-7 99.92%
Masitinib mesylate is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectivel...
T6230 Imatinib 152459-95-5 99.94%
matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).
T2500 Cediranib 288383-20-0 99.94%
Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/...
T4320 Flumatinib 895519-90-1 99.95%
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
T0080 Trapidil 15421-84-8 99.96%
Trapidil is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic ...
T5001 Nintedanib esylate 656247-18-6 99.96%
BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
TN2354 Methylnissolin 73340-41-7 99.98%
3-Hydroxy-9,10-dimethoxyptercarpan is derived from Astragalus and has antibacterial and anti-cancer effects.
Lenvatinib mesylate
T8541
Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
Lenvatinib
T0520
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
Sorafenib tosylate
T0093
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
Flumatinib mesylate
T7861
Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
SKLB 610
T1895
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
ON123300
T6920
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
Pazopanib
T0097L
Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1,...
Regorafenib
T1792
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
KN1022
T60110
KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
Sorafenib
T0093L
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
KI8751
T2446
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
Masitinib
T2609
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
Nintedanib
T1777
Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).
Masitinib mesylate
T8544
Masitinib mesylate is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectivel...
Imatinib
T6230
matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).
Cediranib
T2500
Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/...
Flumatinib
T4320
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
Trapidil
T0080
Trapidil is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic ...
Nintedanib esylate
T5001
BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
Methylnissolin
TN2354
3-Hydroxy-9,10-dimethoxyptercarpan is derived from Astragalus and has antibacterial and anti-cancer effects.
1 2 3 4 5 6